Hyperliquid Strategies Inc (NASDAQ:PURR – Get Free Report) has been given an average rating of “Buy” by the five analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $19.80.
PURR has been the topic of several research analyst reports. Wall Street Zen lowered Hyperliquid Strategies from a “hold” rating to a “sell” rating in a research report on Sunday, October 11th. Compass Point started coverage on Hyperliquid Strategies in a report on Monday, September 14th. They issued a “buy” rating and a $18.00 price objective for the company. Chardan Capital increased their price objective on Hyperliquid Strategies from $9.75 to $17.00 and gave the company a “buy” rating in a report on Friday, August 28th. Cantor Fitzgerald raised their target price on shares of Hyperliquid Strategies from $22.60 to $34.20 and gave the stock an “overweight” rating in a research report on Thursday, September 10th. Finally, Weiss Ratings cut shares of Hyperliquid Strategies from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 23rd.
Read Our Latest Report on Hyperliquid Strategies
Institutional Trading of Hyperliquid Strategies
Hyperliquid Strategies Stock Down 11.8%
Shares of NASDAQ PURR opened at $9.71 on Tuesday. The stock has a market cap of $2.70 billion, a PE ratio of -1.51 and a beta of 1.89. Hyperliquid Strategies has a 52-week low of $3.01 and a 52-week high of $14.76. The business has a 50-day moving average price of $11.41 and a 200 day moving average price of $8.00.
About Hyperliquid Strategies
Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc, is based in NEW YORK.
See Also
- Five stocks we like better than Hyperliquid Strategies
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Hyperliquid Strategies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperliquid Strategies and related companies with MarketBeat.com's FREE daily email newsletter.
